Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleThe University of Oxford's Oxford Vaccine Group has vaccinated the first volunteer in the world's inaugural clinical trial for a vaccine against the Bundibugyo strain of Ebola.This marks the first human administration of the ChAdOx1 BDBV vaccine, which was developed by Oxford scientists using the same technology as the Oxford/AstraZeneca Covid-19 vaccine. Bundibugyo has been tearing through the Democratic Republic of Congo, with 3,262 confirmed cases and 1,437 deaths.The Serum Institute of India has manufactured 620,000 doses of the vaccine in record time and supplied 4,000 investigational doses for the trial. The study team will continue recruiting volunteers, with preparations underway for further clinical studies in Uganda.More bulletinsThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in
First human volunteer vaccinated against Bundibugyo strain of Ebola
Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleThe University of Oxford's Oxford Vaccine Group has vaccinated the first volunteer in the world's inaugural clinical trial for a vaccine against the Bundibugyo strain of Ebola.This marks the first human administration of the ChAdOx1 BDBV vaccine, which was developed by Oxford scientists using the same technology as the Oxford/AstraZeneca Covid-19 vaccine. Bundibugyo has been tearing through the Democratic Republic of Congo, with 3,262 confirmed cases and 1,437 deaths.The Serum Institute of India has manufactured 620,000 doses of the vaccine in record time and supplied 4,000 investigational doses for the trial. The study team will continue recruiting volunteers, with preparations underway for further clinical studies in Uganda.More bulletinsThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in
